These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29715119)

  • 1. Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.
    Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 May; 38(5):2929-2938. PubMed ID: 29715119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Noda S; Takashima T; Onoda N; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    PLoS One; 2017; 12(2):e0170634. PubMed ID: 28166544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Hatano T; Tanaka S; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Jan; 38(1):401-410. PubMed ID: 29277801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment.
    Kashiwagi S; Tsujio G; Asano Y; Goto W; Takada K; Takahashi K; Morisaki T; Fujita H; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    J Transl Med; 2018 Mar; 16(1):54. PubMed ID: 29523158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
    Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
    BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
    Chen S; Wang RX; Liu Y; Yang WT; Shao ZM
    Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
    Goto W; Kashiwagi S; Takada K; Asano Y; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
    Anticancer Res; 2022 Feb; 42(2):939-946. PubMed ID: 35093893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
    Rau KM; Ou-Yang F; Chao TC; Kuo YL; Cheng TF; Chao TY; Chen DR; Tzeng YD; Wang BW; Liu CY; Hu MH; Lu YC; Ou WJ; Kuo CH; Chuang CH; Kan JY; Chen FM; Hou MF
    Breast Cancer Res Treat; 2018 Aug; 170(3):583-591. PubMed ID: 29623575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.
    Kashiwagi S; Fukushima W; Asano Y; Goto W; Takada K; Noda S; Takashima T; Onoda N; Ohsawa M; Hirakawa K; Ohira M
    BMC Cancer; 2017 Aug; 17(1):604. PubMed ID: 28859615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer.
    Takada K; Kashiwagi S; Goto W; Asano Y; Takahashi K; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    J Transl Med; 2018 Apr; 16(1):86. PubMed ID: 29615076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
    Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Togo S; Shimizu H; Saito M
    J Transl Med; 2018 Oct; 16(1):287. PubMed ID: 30342534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.
    Quaquarini E; Sottotetti F; D'Ambrosio D; Malovini A; Morganti S; Marinello A; Pavesi L; Frascaroli M
    Future Oncol; 2017 Apr; 13(11s):11-23. PubMed ID: 28481185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
    Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
    Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
    Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
    Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
    Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
    Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of Systemic and Local Tumour Immune Response to Eribulin Chemotherapy in the Treatment of Breast Cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Morisaki T; Kouhashi R; Yabumoto A; Tanaka S; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2020 Jun; 40(6):3345-3354. PubMed ID: 32487630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
    Miyagawa Y; Araki K; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Nishimukai A; Kira A; Imamura M; Takatsuka Y; Miyoshi Y
    Clin Breast Cancer; 2018 Oct; 18(5):400-409. PubMed ID: 29605174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
    Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
    Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
    Majid O; Gupta A; Reyderman L; Olivo M; Hussein Z
    J Clin Pharmacol; 2014 Oct; 54(10):1134-43. PubMed ID: 24771603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.